Lung Cancer Research Report Site Specific Group Meeting
Lung Cancer Research Report Site Specific Group Meeting Tuesday 11th November 2014 Maxine Taylor Senior Research Delivery Manager Delivering clinical research to make patients, and the NHS, better Content of report Overview of network changes Overview of research activity New studies for the portfolio Request for research lead 2 Introduction NIHR Clinical Research Network merged all cancer research networks with all other clinical research networks in England on 1st April 2014 CRN - West of England is one of 15 new networks
This new geography does not map exactly to the site specific group geography. It now includes Gloucestershire and Swindon but no longer includes Taunton and Yeovil Taunton and Yeovil are served by the CRN South West Peninsula I will work closely with my counterpart in South West Peninsula to support this SSG in full 3 Map showing the 15 Clinical Research Networks in England West of England Population 2.4 million - Budget 13.2 million - 7 Acute Trusts - 2 Mental Health Trusts - CCL Principal Treatment Centre - Full team only since August 1st - Small core support team based at host in Bristol Research will follow patient pathways regardless of network geography Purpose of the network Translation of national workstreams and objectives (generic and specialty specific) with strategic oversight of research activity within the geography of CRN - West of England in
terms of: Portfolio Balance, new studies, feasibility, industry trials Performance Targets, support timely set up, support timely recruitment People Skill mix, workforce flexibility, resources, training 5 CRN - West of England Management Model Division 1 Division 5 Maxine Taylor Senior RDM Workforce Development Martine Cross Senior RDM RM&G and Industry Lead Mary Perkins Chief Operating Officer
Chantal Sunter RDM PCPIE and Comms Lead Divisions 3 & 4 Ruth Allen RDM Business Intelligence lead Division s2&6 Network Clinical Divisions Division 1 Cancer Division 2 Diabetes Stroke Cardiovascular Renal Metabolic & endocrine
Division 3 Children Genetics Division 4 Mental Health Dementias & neurodegenerative diseases Neurology Division 5 Primary care research Oral & dental Musculoskeletal Ageing Division 6
Anaesthesia & pain management Critical care Opthalmology Infectious diseases Gastroenterology ENT Surgery Respiratory Critical care Hepatology Reproductive health & childbirth Haematology Health services Dermatology Public Health The Clinical Team Dr Steve Falk Clinical Director 6 Divisional Clinical Leads Prof Hugh Barr for Div 1 30 Specialty
Leads Sub Specialty Leads Sue Taylor Network Consultant Nurse Clinical Research Teams NIHR CRN High Level Objectives Set up as fast as you can Recruit as many and as fast as you can All organisations involved Commercial and non commercial portfolio studies Cancer specialty specific objectives Recruitment overall at 20% cancer incidence Recruitment to interventional studies at 7.5% of cancer incidence
How important is cancer on our patch? Research staff WTE per division 58 67 23 34 17 20 21 Div 1 Div 2 Div 3 Div 4 Div 5 Div 6 Generic
Cancer incidence 9544 242 recruiting studies 2 million (16%) Funding per incident case approx 220 Funding per recruit 800 Exceeded both recruitment targets for last 2 years Largest non commercial portfolio Benefit from continued good national and international links West of England specialty portfolio compared to national Surgery Stroke Respiratory disorders Reproductive health and childbirth Renal disorders Public health Primary Care Oral and dental health Ophthalmology Neurological disorders Musculoskeletal disorders
Metabolic and endocrine disorders Mental Health Injuries and emergencies Infectious diseases and microbiology Hepatology Health services and delivery research Haematology Genetics Gastroenterology Ear, nose and throat Diabetes Dermatology Dementias and neurodegeneration Critical care Children Cardiovascular disease Cancer Anaesthesia, perioperative medicine and pain Ageing Total studies 3827 WE total 546 =14% National portfolio WE portfolio 0
100 200 300 400 500 600 700 800 CRN: West of England Performance against goals 14/15 (Apr 2014 - Sep 2014) 5000 4500 4000 3500 3000 2500 2000 1500 1000 500
0 Data extracted: 27 Oct 14 Recruitment (Apr 2014 - Sep 2014) Recruitment goal (Apr 2014 - Sep 2014) Recruitment goal 2014/15 Primary Care goal 14/15: 9224 Recruitment by Trust and study design April Oct 2014 45 40 35 30 25 Observational Interventional 20 15 10 5 0
Glos Swindon NBT Bath UHB Weston 13 Recruitment by Trust and study April Oct 2014 45 40 DIAPHRAGM 35 Investigation of pleural disease: improving the patient pathway 1 30 Lung ART LungCAST
25 MEDLUNG 20 NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC 15 NCRN533 - Met inhibitor+/- Erlotinib in Met+ Eroltinib resistant NSCLC NCRN552- ASCEND V 10 QUARTZ 5 STOMP TIMELY 0 14 WE Lung portfolio
Gloucestershire Hospitals NHS Foundation Trust LungCAST NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC NCRN552- ASCEND V Great Western Hospital MEDLUNG North Bristol NHS Trust DIAPHRAGM Investigation of pleural disease: improving the patie nt pathway 1 NCRN533 - Met inhibitor+/- Erlotinib in Met+ Eroltinib resistant NSCLC University Hospitals Bristol NHS Foundation Trust Lung ART QUARTZ STOMP Weston Area Health NHS Trust QUARTZ TIMELY Grand Total 14 10 2 2 11 11 42 0 41
1 1 0 0 1 3 3 0 71 15 New studies to discuss: Portfolio search criteria open to new sites with >12 months to run SPUtNIk - Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodule Closure date March 2017 CI Dr Steve George, Southampton TAPPS - Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry: a randomised trial to determine the most effective method for the management of malignant pleural effusions in patients with a good performance status Closure date Jan 2017 CI Dr Nick Maskell, NBT, Bristol MARS2
A study to determine if it is feasible to recruit into a randomised trial comparing (extended) pleurectomy decortication versus no pleurectomy decortication in the multimodality management of patients with malignant pleural mesothelioma 16 IN SET UP. CI Dr Eric Lim, Royal Brompton, London New studies continued CEDAR - A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX427) in advanced squamous cell lung cancers Closure date Dec 2016 CI Prof Peter Schmid, Queen Marys, London 17 Commercial studies NCRN569- LDK378 in ALK+ advanced NSCLC - ASCEND IV - A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), locally advanced or metastatic, non-squamous non-small cell lung cancer NCRN552- ASCEND V - A phase III, multicenter, randomized, openlabel study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy
(platinum doublet) and crizotinib NCRN - 2974 VESTA: Veliparib, carboplatin & paclitaxel in NSCLC - A Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib PlusCarboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously UntreatedAdvanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 18 Cancer Subspecialty Research Leads Within each network 13 subspecialty research lead roles are identified, mapping onto the national Clinical Studies Groups with the aim of: Providing link between local network and CSGs Promoting the research agenda to clinical colleagues across the network Advising on portfolio planning locally Attendance at annual meeting to discuss portfolio planning and delivery and horizon scan for new studies Supporting the research delivery manager for the cancer specialty Role very similar to SSG Research Lead role 19 National Clinical
Studies Groups Psychosocial & Survivorship Brain Tumours Head & CSG Palliative & Neck Supportive CSG Care Sarcoma CSG Breast Cancer CSG Imaging Adv. panel Lung Cancer CSG Upper GI Biomarkers Adv. panel
Cancer CSG Colorectal Cancer Consumer CSG Melanoma Liaison PPI Kidney CSG Group Cancer Primary CSG Lymphoma Care Bladder CSG Cancer Screening, Testis CSG Haematol. Prevention & Cancer CSG Prostate Gynae Early Diagnosis
CSG Childrens Cancer Cancer Cancer & CSG CSG Teenage & Leukaemia Young Adult CTRad (Radiotherapy) LCRN (x15) CRN WE Exec Board Partnership Group Clin. Advisory Group Clinical Director COO Division 1 Clinical Lead Division 1 RDM [ +/- other clinical roles] 13 LCRN Subspecialty Leads:
Brain cancer H&N cancer Lung cancer Breast cancer Sarcoma Skin Cancer Children/young people Upper GI cancer Colorectal cancer Urological cancer Gynae cancer Haem/lymphoma Pall/Supportive & Psychosocial Research Delivery Teams Call for Lung sub-specialty lead in CRN - West of England Each SSG already has a research lead We are looking for a research lead in each tumour site to represent the network locally and nationally in terms of developing and supporting the portfolio and providing clinical specialty support to the Research Delivery Manager and Principal Investigators across the network Expenses to attend national meetings will be met by the
network Please discuss: Your current research lead continuing and taking on the network representation The nomination of a new research lead who will take on network representation 22 Contact & reference details [email protected][email protected] http://csg.ncri.org.uk/portfolio-maps/ https://www.edge.nhs.uk/Account/Index?ReturnUrl=%2f http ://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcr n-portfolio / 23
Uses a backward pass to transitively recover object death points. Hundreds of times slowdown even for small programs (e.g., 752X for DaCapo-small) GC-based approximation. The collection of an object is treated as its death. Imprecise for many applications (e.g., all...
Can you think of any other equal but opposite force pairs? Third Law Perhaps you came up with: When a baseball hits a bat The bat exerts a force on the ball and the ball exerts an equal but opposite...
All year the flax-dam festered in the heartOf the townland; green and heavy headedFlax had rotted there, weighted down by huge sods.Daily it sweltered in the punishing sun.Bubbles gargled delicately, bluebottlesWove a strong gauze of sound around the smell.There were...
The Second Law of Thermodynamics Chapter 7 The first law of thermodynamics states that during any cycle that a system undergoes, the cyclic integral of the heat is equal to the cyclic integral of the work. However, we know from...
Strategic Alignment is covered later in this plan. Guideline: Keep to one page and condense as needed. Purpose: Used to communicate the project objective, and background. Cut and paste from the project background information in the PID, and cut and...
Aus: Primo Passo Italienischkurs für Anfänger von Liborio Pepi Zeichnungen von Lucio Pepi Gottfried egert verlag isbn 3-926972-98-x Come ti chiami? Wie heißt du? Chiamarsi heißen Io mi chiamo Tu ti chiami lui/lei si chiama Noi ci chiamiamo Voi vi...
Draft COLLECTIVE AGREEMENT on amendments to paragraph B.8.5 of Chapter B and the repeal of paragraph H.17 of Chapter H of the Personnel Administrative Measures: DG MEETING WITH UNIONS ... The administration of the study is managed by the Centre...
Ready to download the document? Go ahead and hit continue!